Other formats:
BibTeX
LaTeX
RIS
@article{1323995,
author = {Fiala, Ondrej and Pesek, Milos and Finek, Jindrich and Topolcan, Ondrej and Racek, Jaroslav and Minarik, Marek and Benesova, Lucie and Bortlíček, Zbyněk and Poprach, Alexandr and Buchler, Tomas},
article_location = {Dordrecht},
article_number = {12},
doi = {http://dx.doi.org/10.1007/s13277-015-3660-3},
keywords = {C-reactive protein; Lung cancer; NSCLC; EGFR-TKI; Erlotinib; Prediction; Biomarker},
language = {eng},
issn = {1010-4283},
journal = {Tumor Biology},
title = {High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib},
volume = {36},
year = {2015}
}
TY - JOUR
ID - 1323995
AU - Fiala, Ondrej - Pesek, Milos - Finek, Jindrich - Topolcan, Ondrej - Racek, Jaroslav - Minarik, Marek - Benesova, Lucie - Bortlíček, Zbyněk - Poprach, Alexandr - Buchler, Tomas
PY - 2015
TI - High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib
JF - Tumor Biology
VL - 36
IS - 12
SP - 9215-9222
EP - 9215-9222
PB - Springer
SN - 10104283
KW - C-reactive protein
KW - Lung cancer
KW - NSCLC
KW - EGFR-TKI
KW - Erlotinib
KW - Prediction
KW - Biomarker
N2 - Erlotinib is a low molecular weight tyrosine kinase inhibitor (TKI) directed at epidermal growth factor receptor (EGFR), widely used in the treatment of locally advanced or metastatic-stage non-small cell lung cancer (NSCLC). Although introduction of EGFR-TKIs have significantly extended survival of advanced-stage NSCLC patients, their efficacy in the entire patient population is relatively low. Aside from activating EGFR mutations, no reliable biochemical or molecular predictors of response to erlotinib have been established. The aim of our retrospective study was to evaluate the association of baseline serum levels of C-reactive protein (CRP) with outcomes in patients with advanced-stage NSCLC treated with erlotinib. We retrospectively analyzed clinical data of 595 patients with advanced-stage NSCLC (IIIB or IV) treated with erlotinib. Serum CRP was measured using an immunoturbidimetric method. High baseline levels of CRP (>=10 mg/l) were measured in 387 (65 %) patients, and normal levels (<10 mg/l) were measured in 208 (35 %) patients. The median progression-free survival (PFS) and overall survival (OS) for patients with high CRP was 1.8 and 7.7 compared to 2.8 and 14.4 months for patients with low CRP (p<0.001 and p<0.001). The multivariable Cox proportional hazards model revealed that CRP was significantly associated with PFS and also with OS (hazard ratio (HR)=1.57, p<0.001, and HR=1.63, p<0.001, respectively). In conclusion, the results of the conducted retrospective study suggest that high baseline level of CRP was independently associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. CRP is a commonly used biomarker which is simple and easy to detect, and thus, it is feasible for the use in the routine clinical practice.
ER -
FIALA, Ondrej, Milos PESEK, Jindrich FINEK, Ondrej TOPOLCAN, Jaroslav RACEK, Marek MINARIK, Lucie BENESOVA, Zbyněk BORTLÍČEK, Alexandr POPRACH and Tomas BUCHLER. High serum level of C-reactive protein is associated with worse outcome of patients with advanced-stage NSCLC treated with erlotinib. \textit{Tumor Biology}. Dordrecht: Springer, 2015, vol.~36, No~12, p.~9215-9222. ISSN~1010-4283. Available from: https://dx.doi.org/10.1007/s13277-015-3660-3.
|
